Xconomy’s Digital Events →
With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA... Read more »
Sponsored · Webinar
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals